Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline
暂无分享,去创建一个
M. Mena | M. Casarejos | J. D. Yébenes | M J Casarejos | R M Solano | J Menéndez | J A Rodríguez-Navarro | J García de Yébenes | M A Mena | J. García de Yébenes | R. Solano | J. Rodríguez-Navarro | J. Menéndez
[1] S. Canals,et al. Neurotrophic and neurotoxic effects of nitric oxide on fetal midbrain cultures , 2001, Journal of neurochemistry.
[2] M. Beal,et al. Experimental models of Parkinson's disease , 2001, Nature Reviews Neuroscience.
[3] V. Uversky,et al. The Herbicide Paraquat Causes Up-regulation and Aggregation of α-Synuclein in Mice , 2002, The Journal of Biological Chemistry.
[4] T. Decker,et al. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. , 1988, Journal of immunological methods.
[5] E. Joe,et al. Gangliosides Activate Cultured Rat Brain Microglia* , 1999, The Journal of Biological Chemistry.
[6] A. Gropp,et al. pH-dependent fluorescence of DNA and RNA in cytologic staining with “33258 Hoechst” , 1975 .
[7] S. Canals,et al. Nitric oxide induces differentiation in the NB69 human catecholamine-rich cell line , 2000, Neuropharmacology.
[8] G. Kreutzberg,et al. Lectin binding by resting and reactive microglia , 1987, Journal of neurocytology.
[9] F. Zoccarato,et al. Dopamine-derived dopaminochrome promotes H(2)O(2) release at mitochondrial complex I: stimulation by rotenone, control by Ca(2+), and relevance to Parkinson disease. , 2005, The Journal of biological chemistry.
[10] K. Heidenreich,et al. The pesticide rotenone induces caspase‐3‐mediated apoptosis in ventral mesencephalic dopaminergic neurons , 2003, Journal of neurochemistry.
[11] A. H. V. Schapira,et al. MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.
[12] S. Przedborski,et al. Oxidative Stress in Parkinson's Disease , 2008, Annals of the New York Academy of Sciences.
[13] Carlos Matute,et al. Neuroprotection by tetracyclines. , 2004, Trends in pharmacological sciences.
[14] J. Menéndez,et al. Effects of cinnarizine, a calcium antagonist that produces human parkinsonism, in parkin knock out mice , 2005, Neuropharmacology.
[15] J. Brotchi,et al. Clinical potential of minocycline for neurodegenerative disorders , 2004, Neurobiology of Disease.
[16] Todd B. Sherer,et al. Subcutaneous Rotenone Exposure Causes Highly Selective Dopaminergic Degeneration and α-Synuclein Aggregation , 2003, Experimental Neurology.
[17] V. Uversky,et al. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. , 2002, The Journal of biological chemistry.
[18] M. Mena,et al. Differential effects of l‐DOPA on monoamine metabolism, cell survival and glutathione production in midbrain neuronal‐enriched cultures from parkin knockout and wild‐type mice , 2005, Journal of neurochemistry.
[19] M. Vila,et al. The role of glial cells in Parkinson's disease , 2001, Current opinion in neurology.
[20] Todd B. Sherer,et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.
[21] Joachim Klose,et al. Mitochondrial Dysfunction and Oxidative Damage in parkin-deficient Mice* , 2004, Journal of Biological Chemistry.
[22] Jean Féger,et al. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats , 2003, Journal of neurochemistry.
[23] C. Marsden,et al. Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.
[24] G. Hardy,et al. Mendelian proportions in a mixed population. 1908. , 1908, Zeitschrift für induktive Abstammungs- und Vererbungslehre.
[25] S. Canals,et al. Glia‐conditioned medium induces de novo synthesis of tyrosine hydroxylase and increases dopamine cell survival by differential signaling pathways , 2003, Journal of neuroscience research.
[26] Santiago Canals,et al. The role of astroglia on the survival of dopamine neurons , 2002, Molecular Neurobiology.
[27] Todd B. Sherer,et al. Mechanism of Toxicity in Rotenone Models of Parkinson's Disease , 2003, The Journal of Neuroscience.
[28] Neuronal-enriched cultures from embryonic rat ventral mesencephalon for pharmacological studies of dopamine neurons. , 1997, Brain research. Brain research protocols.
[29] Lloyd A Greene,et al. Endoplasmic Reticulum Stress and the Unfolded Protein Response in Cellular Models of Parkinson's Disease , 2002, The Journal of Neuroscience.
[30] S. Ben‐Sasson,et al. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation , 1992, The Journal of cell biology.
[31] Y. Kawaoka,et al. Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice , 2000, Nature Medicine.
[32] Seung U. Kim,et al. Thrombin-Induced Microglial Activation Produces Degeneration of Nigral Dopaminergic Neurons In Vivo , 2003, The Journal of Neuroscience.
[33] M. Allam,et al. Parkinson's disease risk factors: genetic, environmental, or both? , 2005, Neurological research.
[34] E. Hirsch,et al. Nitric oxide, glial cells and neuronal degeneration in parkinsonism. , 2000, Trends in pharmacological sciences.
[35] A. Wyllie,et al. Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.
[36] D. D. Di Monte. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? , 2003, The Lancet. Neurology.
[37] S. Paul,et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[38] Todd B. Sherer,et al. Selective microglial activation in the rat rotenone model of Parkinson's disease , 2003, Neuroscience Letters.
[39] Betty Y. S. Kim,et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice , 2002, Nature.
[40] A. Dick,et al. Minocycline delays photoreceptor death in the rds mouse through a microglia-independent mechanism. , 2004, Experimental eye research.
[41] V. Uversky,et al. Pesticides directly accelerate the rate of α‐synuclein fibril formation: a possible factor in Parkinson's disease , 2001, FEBS letters.
[42] R. Ramsay,et al. Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+. , 1986, Biochemical and biophysical research communications.
[43] I. Miyazaki,et al. Rotenone induces aggregation of γ-tubulin protein and subsequent disorganization of the centrosome: Relevance to formation of inclusion bodies and neurodegeneration , 2005, Neuroscience.
[44] G. Hardy. MENDELIAN PROPORTIONS IN A MIXED POPULATION. , 1908 .
[45] S. Schiffmann,et al. Minocycline in phenotypic models of Huntington's disease , 2005, Neurobiology of Disease.
[46] Cytotoxicity of microglia , 1993 .
[47] L. Tremblay,et al. Experimental Models of Parkinson’s Disease , 2002, Annales pharmaceutiques francaises.
[48] Y. Hiraku,et al. Mechanism for generation of hydrogen peroxide and change of mitochondrial membrane potential during rotenone-induced apoptosis. , 2003, Life sciences.
[49] Werner J. Schmidt,et al. Chronic administration of rotenone increases levels of nitric oxide and lipid peroxidation products in rat brain , 2004, Experimental Neurology.
[50] Santiago Canals,et al. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. , 2003, Human molecular genetics.
[51] T. Hökfelt,et al. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[52] K. Ashwell,et al. The distribution of microglia and cell death in the fetal rat forebrain. , 1991, Brain research. Developmental brain research.
[53] S. Hersch,et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease , 2000, Nature Medicine.
[54] S. Birman,et al. Chronic Exposure to Rotenone Models Sporadic Parkinson's Disease in Drosophila melanogaster , 2004, The Journal of Neuroscience.
[55] Donato A Di Monte,et al. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? , 2003, The Lancet Neurology.
[56] Dong-Kug Choi,et al. Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease , 2002, The Journal of Neuroscience.
[57] S. Paul,et al. Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons , 2001, Neuroscience Letters.
[58] R. Ramsay,et al. Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism. , 1986, Biochemical and biophysical research communications.
[59] B. Fiebich,et al. Minocycline, a Tetracycline Derivative, Is Neuroprotective against Excitotoxicity by Inhibiting Activation and Proliferation of Microglia , 2001, The Journal of Neuroscience.
[60] Bin Liu,et al. Critical Role for Microglial NADPH Oxidase in Rotenone-Induced Degeneration of Dopaminergic Neurons , 2003, The Journal of Neuroscience.
[61] M. Mena,et al. Glia protect fetal midbrain dopamine neurons in culture from L-DOPA toxicity through multiple mechanisms , 2005, Journal of Neural Transmission.
[62] Nicolas Lapointe,et al. Rotenone induces non‐specific central nervous system and systemic toxicity , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[63] A J Lees,et al. When did Ray Kennedy's Parkinson's disease begin? , 1992, Movement disorders : official journal of the Movement Disorder Society.
[64] W. Tatton,et al. Etiology and pathogenesis of Parkinson's disease. , 1999, Annual review of neuroscience.
[65] G. Kreutzberg,et al. Cytotoxicity of microglia , 1992, Journal of Neuroimmunology.
[66] A. Brice,et al. Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function , 2005, Journal of neurochemistry.
[67] W. Nicklas,et al. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.
[68] W. Schmidt,et al. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats , 2002, Behavioural Brain Research.
[69] Wenhua Zhang,et al. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS , 2003, Annals of neurology.
[70] Todd B. Sherer,et al. An In Vitro Model of Parkinson's Disease: Linking Mitochondrial Impairment to Altered α-Synuclein Metabolism and Oxidative Damage , 2002, The Journal of Neuroscience.
[71] J. Koistinaho,et al. Minocycline Provides Neuroprotection Against N-Methyl-d-aspartate Neurotoxicity by Inhibiting Microglia1 , 2001, The Journal of Immunology.
[72] Y. Moon,et al. Mitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone: protective effect of coenzyme Q10 , 2005, Journal of neurochemistry.
[73] W. Dauer,et al. Parkinson's Disease Mechanisms and Models , 2003, Neuron.
[74] W. Le,et al. Minocycline: neuroprotective mechanisms in Parkinson's disease. , 2004, Current pharmaceutical design.
[75] Ming-tao Li,et al. Minocycline prevents glutamate‐induced apoptosis of cerebellar granule neurons by differential regulation of p38 and Akt pathways , 2004, Journal of neurochemistry.